Aa
A
A
A
Close
Hepatitis B Community
7.17k Members
9624973 tn?1413016130

Replicor to participate at the 6th DIA / FDA Oligonucleotide-Based conf

NEW YORK, Sept 3 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will be an invited participant at the 6th DIA / FDA Oligonucleotide-Based Therapeutics Conference to be held September 9-11, 2015 in Washington. This conference is jointly convened by the DIA (Develop Innovate Advance) organization and the US Food and Drug Administration to showcase and educate on advances, safety and challenges in the field of oligonucleotide-based therapeutics.

Replicor will present an overview of mechanism of action and current clinical experience with its nucleic acid polymer (NAP) technology for the treatment of chronic HBV infection and HBV / HDV co-infection.
0 Responses
Have an Answer?
Didn't find the answer you were looking for?
Ask a question
Popular Resources
For people with Obsessive-Compulsive Disorder (OCD), the COVID-19 pandemic can be particularly challenging.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.
In You Can Prevent a Stroke, Dr. Joshua Yamamoto and Dr. Kristin Thomas help us understand what we can do to prevent a stroke.